Cancer screening in the elderly — currently accepted strategies

Screening is secondary prevention — detection of disease in the preclinical phase. Essentials states that the value of screening depends on the availability of an effective intervention and the likelihood that the intervention will change the clinical course.

In the elderly, three questions must be answered before screening: Is life expectancy long enough to benefit? Will the patient accept diagnostic work-up and treatment? Do benefits outweigh harms?

The "10-year rule" — most guidelines advise continuing screening only if life expectancy is 10 years or more, because that is the lag time to mortality benefit for breast and colorectal cancer.

Cancer biology may differ in old age: although incidence and prevalence rise with age, the rate of growth may be slower, which increases the risk of overdiagnosis.

Essentials gives sobering figures: the mean age of detection of the commonest cancers is about 68 and the mean age of death about 72. For breast cancer, median age at diagnosis is ~61 and at death ~69.

Pathy's screens by functional category, not chronological age — Robust, Frail, Moderately demented, End of life.

Mammography is the mainstay, and research has shown it to be effective up to age 84.

There is no agreement on when to stop. ACS: annual from 55, or transition to biennial, continuing if overall health is good and life expectancy ≥10 years. NCCN: annual, with no stopping age. USPSTF (textbook version): biennial up to 74.

Self-examination and clinical breast examination are contested — NCCN recommends both, ACS recommends breast self-awareness if the woman is interested, and USPSTF recommends against both.

Few studies describe how women decide to stop; many discontinue after a serious health event, recognising that benefit falls with remaining life expectancy.

Stop screening at 65 if there have been three or more consecutive negative Pap tests, or at least two consecutive negative HPV-and-Pap tests within the past 10 years, with the most recent within 5 years.

Women who had a hysterectomy for benign disease can stop.

Continue in older women with inadequate or unknown screening history, prior high-grade lesion or cervical cancer, in-utero DES exposure, or immunocompromise. Essentials warns that cervical cancer remains a serious risk in older women and that risk rises with longer inter-test intervals — highly relevant in India, where most older women have never been screened even once.

Structural examination of the colon is one of the most effective means of preventing colorectal cancer, because polyps can be found and removed before malignant change.

Start at 50 (USPSTF, NCCN) or 45 (ACS). All three recommend individualised decisions in adults aged 76–85; USPSTF recommends against screening above 85.

Options: FOBT or FIT-DNA every 3 years, flexible sigmoidoscopy every 5 years; colonoscopy is more thorough and is the preferred option. Structural tests detect polyps; stool tests detect cancers.

Limit screening in frail individuals and patients with dementia. Essentials notes that most clinicians would not be enthusiastic about subjecting an 85-year-old to colonoscopy.

No major organisation — ACS, AUA, USPSTF, AAFP or ACPM — supports routine PSA testing. ACS: from age 50, informed discussion if life expectancy ≥10 years; NCCN: PSA only if life expectancy ≥10 years; USPSTF recommends against screening in men 70 and older.

The core problem is overdiagnosis — many prostate cancers grow slowly and would never cause harm, yet surgery or radiation produces incontinence and impotence that seriously affect quality of life.

Low-dose CT reduces lung cancer mortality by about 20% compared with chest X-ray in current or former heavy smokers. ACS: annual LDCT age 55–74, ≥30 pack-years, quit within 15 years, good health, after shared decision-making. NCCN: stop at 77. USPSTF (textbook version): 55–80.

Stop LDCT once the person has not smoked for 15 years, or develops a health problem that substantially limits life expectancy or the ability or willingness to undergo curative lung surgery. LDCT is never an alternative to smoking cessation.

Not recommended at any age: USPSTF gives a grade D against routine ovarian cancer screening.

Breast — USPSTF revised in April 2024. The Task Force now recommends biennial screening mammography for women aged 40 to 74 (B recommendation); for women 75 years or older the evidence remains insufficient (I statement), as it does for supplemental ultrasound or MRI in dense breasts (JAMA/USPSTF, 2024). The change was estimated to save 19% more lives than the previous "start at 50" position. The key geriatric point is unchanged: above 75, the decision is individualised on life expectancy and comorbidity, not on evidence.

Cervical — the biggest change is self-collection. USPSTF recommends cytology every 3 years at 21–29 and HPV testing every 5 years at 30–65, and for the first time endorses self-collected HPV samples, which are as accurate as clinician-collected and increase uptake in under-screened groups; it continues to recommend against screening women over 65 who have had adequate prior screening (USPSTF, 2024–25). The American Cancer Society updated its guideline in December 2025 — screening from age 25 with primary HPV testing every 5 years through 65, with self-collected vaginal specimens acceptable and new guidance on when to safely exit screening. HRSA's Women's Preventive Services Guidelines were updated in January 2026 to prefer primary hrHPV testing every 5 years for ages 30–65.

Colorectal — start age lowered. USPSTF (2021, still current) recommends screening from 45 to 75 years, with selective screening at 76–85 (grade C). The elderly-specific decision point is unchanged, but the entry age has moved from 50 to 45.

Lung — eligibility broadened. USPSTF (2021) now recommends annual LDCT from age 50 to 80 in adults with a ≥20 pack-year history who currently smoke or quit within 15 years — a lower age and lower pack-year threshold than the textbook figures.

Prostate — unchanged but clarified. USPSTF (2018): shared decision-making at 55–69 (grade C) and against PSA screening at 70 and above (grade D).

India — a population-based programme now exists, but it stops at 65. NPCDCS was renamed the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) in May 2023. Under this programme, oral, breast and cervical cancer screening is free at Health and Wellness Centres for adults aged 30 to 65, with community health workers identifying eligible individuals; ICMR recommends clinical breast examination every 1–3 years as the practical starting point in India. The Operational Framework for Management of Common Cancers notes that breast, cervix and oral cancers together account for about 34% of all cancers in India, and recommends oral cancer screening for all adults over 30.

Indian coverage data. As of July 2025, 10.18 crore of an eligible 25.42 crore women aged ≥30 had been screened for cervical cancer through Ayushman Arogya Mandirs, primarily with visual inspection with acetic acid (VIA) at sub-centres and PHCs, with VIA-positive cases referred upward (Ministry of Health, 2025). However, a 2025 review found that fewer than 2% of eligible women aged 30–49 had actually been screened for cervical or breast cancer at the time of the 2019–21 national survey (Asian Pacific Journal of Cancer Prevention, 2025).

Resource-stratified Indian guidance. The National Cancer Grid consensus guidelines recommend VIA for women 30–65, one to three times in a lifetime, in low-resource settings; HPV testing every 10 years in enhanced-resource settings; and HPV testing every 5 years for ages 25–65 in high-resource settings.

Decision aids are now standard practice. Current geriatric oncology practice emphasises life-expectancy estimation (e.g. ePrognosis calculators), "lag time to benefit" framing, and explicit de-implementation of screening when life expectancy falls below the lag time — with counselling framed around "your other health conditions matter more than this test now" rather than "you are too old".